Health Canada approves Opdivo (nivolumab) plus Yervoy (ipilimumab) as the first and only immunotherapy treatment for previously untreated unresectable malignant pleural mesothelioma

BMS

2 June 2021 - First new systemic therapy in more than 15 years for cancer related to asbestos exposure.

Today, Bristol Myers Squibb Canada announced Health Canada’s approval of Opdivo (nivolumab) 360 mg every three weeks or 3mg/kg every two weeks plus Yervoy (ipilimumab) 1 mg/kg every six weeks (injections for intravenous use) for the treatment of adult patients with unresectable malignant pleural mesothelioma (MPM) who have not received prior systemic therapy for MPM.

Read BMS press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , Medicine , Canada